FORWARD II ASCO Abstract | IMGN Message Board Posts

ImmunoGen, Inc.

  IMGN website

IMGN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  49458 of 49707  at  5/15/2019 8:53:10 PM  by

Bibliobiftek


Re: FORWARD II ASCO Abstract

This is the same set of patients, but notice that the ORR is better now at 56% than the 50% achieved at interim.
 
In FORWARD II's combination with Bevacizumab, Mirv. S. is meant to replace the chemo component typically used with Bev. Note that FORWARD II doesn't have the same restrictions on enrollment as FORWARD I or AURELIA without requirements for FR-alpha expression or number of prior therapies; here was 3 the median number of therapies (1-8 possible) vs a maximum of 2 for AURELIA.
 
They achieved parity with AURELIA results overall with a sicker population and fewer side effects but were markedly superior for patients who have had fewer prior therapies and have med/high FR-alpha expression and/or were Bev. naive.
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 261
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2018 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...